APASL2012 REP9AC'诱导表面抗原转阴后短期免疫诱导持久免疫控

齐欢畅2

In February 2009, the company received an IRB approval to initiate phase I/II trial in patients with HCV and HBV
infections in Asia. The subjects would receive escalating doses of the drug to determine its safe and effective
dose. The primary endpoints were reduction in serum viral titers and serum surface antigen levels and at that
time, patient enrollment was underway [ 1087461]; in March 2009, the company initiated dosing of patients in
its phase I/II trial [ 1087465]. In March 2010, the interim data showed that the drug cleared the serum HBsAg
within the first 12 weeks of treatment by detecting the anti- HBsAg antibodies. These results demonstrated that
sustained reductions in serum HBV titers may be due to improved immune response. The company planned to
present this data in the 20th annual meeting of the APASL in Beijing, China

齐欢畅2

从2009年到2013年，基本上四年过去了，消息还是不怎么确实，如果有加拿大的战友，倒可以去加拿大相关的地方走访看看，还有就是学生物医学之类的战友可以找找他们的论文，做做整理，从专业角度分析分析这个药的作用。

StephenW

回复 齐欢畅2 的帖子

"好像药物对多种病毒都有效果" - 不是"药物", 是分子,化合物, 等等. 对多种病毒都有效果, 这是很容易的, 困难的是：
1对身体有害?
2任何副作用?
3如何送交至目标?

齐欢畅2

好吧，关注吧，我想总有一天会真相大白的。

咬牙硬挺

沉寂了半年，终于又动作了一下，继续关注吧，真的假不了，假的真不了

诗意栖居

个人以为这个是老外瞎忽悠的